vTv Therapeutics (VTVT) Reports Q2 Loss of $0.47/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. LMT
10. SBUX

Go back to vTv Therapeutics (VTVT) Reports Q2 Loss of $0.47/Share

vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes

August 16, 2016 7:00 AM EDT

TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential

Company Releases Q2 Earnings Results and Details Upcoming Program Milestones

HIGH POINT, N.C.--(BUSINESS WIRE)-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimers disease and diabetes, today announced the completion of enrollment of the companys Phase 2 LOGRA (aLlosteric Oral Glp1 Receptor Agonist) study, a randomized, double-blind, placebo-controlled, parallel group trial... More